In our previous post, we discussed the role of the International Council for Harmonization (ICH) in establishing harmonized regulatory guidelines for pharmacovigilance. However, global drug safety does not rely solely on ICH.
Two key international organizations also play a major role in shaping pharmacovigilance concepts and practices: the Council for International Organizations of Medical Sciences (CIOMS) and the World Health Organization (WHO).
While ICH focuses mainly on regulatory harmonization, CIOMS and WHO contribute to the scientific, ethical, and public health foundations of pharmacovigilance. Their guidance supports consistent drug safety monitoring across countries, healthcare systems, and patient populations.
Understanding the roles of CIOMS and WHO is essential for professionals in pharmacovigilance for several reasons:
- Their recommendations influence global safety practices.
This post will explain what CIOMS and WHO are, how they contribute to pharmacovigilance, and why their roles are important for both newcomers and experienced professionals in the field.
Regulatory authorities worldwide rely on their frameworks for decision-making.
While ICH provides harmonized regulatory requirements, organizations like CIOMS and WHO strengthen the scientific, ethical, and public health foundations that support effective pharmacovigilance worldwide.
The Council for International Organizations of Medical Sciences (CIOMS) is an international, non-governmental, non-profit organization established in 1949 jointly by the World Health Organization (WHO) and UNESCO.
CIOMS represents a broad section of the global biomedical scientific community, including:
- National academies of sciences
- Medical research councils
- Professional biomedical organizations
The mission of CIOMS is to advance public health by developing scientific and ethical guidance related to:
- Health research
- Medical product development
- Pharmacovigilance and medicine safety
CIOMS works in official relations with WHO and acts as a scientific advisory body that supports global health decision-making.
Role of CIOMS in Pharmacovigilance
CIOMS plays a foundational role in pharmacovigilance by providing conceptual, scientific, and ethical guidance that supports safe use of medicines throughout their lifecycle.
Unlike regulatory bodies, CIOMS does not issue legally binding rules. Instead, it develops internationally accepted recommendations that are widely followed by:
- Regulatory authorities
- Pharmaceutical companies
- Clinical researchers
- Pharmacovigilance professionals
These recommendations influence how adverse events are assessed, how safety data is interpreted, and how benefit–risk decisions are made globally.
Key Contributions of CIOMS to Pharmacovigilance
1. CIOMS and Adverse Event Reporting
CIOMS contributed to the early development of standardized adverse event reporting formats, which helped harmonize safety data collection during:
- Clinical trials
- Post-marketing surveillance
These concepts later influenced global pharmacovigilance standards, including ICH safety guidelines.
2. CIOMS and Causality Assessment
CIOMS provided the scientific principles used to assess the relationship between a suspected drug and an adverse event.
CIOMS guidance emphasizes evaluating:
- Temporal relationship between drug exposure and event onset
- Dechallenge and rechallenge information
- Presence of alternative causes (disease, alcohol, concomitant drugs)
- Existing knowledge of the drug’s safety profile
While CIOMS did not publish a formal causality “scale,” its concepts strongly influenced the WHO-UMC causality assessment system, which is now widely used in routine pharmacovigilance practice.
đź“Ś Key point: CIOMS provides the conceptual framework, while WHO-UMC provides the practical classification system.
CIOMS Working Groups (Scientific Guidance) |
CIOMS develops its guidance through expert working groups, each addressing key pharmacovigilance challenges.
Important CIOMS working groups include:
Important CIOMS working groups include:- CIOMS I – International reporting of adverse drug reactions
- CIOMS II – International reporting of periodic safety information
- CIOMS III – Core clinical safety information
- CIOMS V – Current challenges in pharmacovigilance
- CIOMS VI – Risk management and safety planning
- CIOMS VIII – Signal detection
- CIOMS XI – Evidence synthesis and benefit–risk assessment
These reports laid the groundwork for:
4. CIOMS and Signal Detection
CIOMS guidance supports systematic approaches to signal detection, including:
- Evaluation of spontaneous adverse event reports
- Review of clinical trial and post-marketing data
- Assessment of consistency, strength, and plausibility of safety signals
CIOMS emphasizes scientific judgment and evidence integration, rather than relying on a single data source.
5. CIOMS and Benefit–Risk Assessment
CIOMS introduced structured thinking around benefit–risk evaluation, helping determine whether a medicine’s benefits continue to outweigh its risks.
This concept later influenced:
- ICH E2C(R2) – Periodic Benefit–Risk Evaluation Reports (PBRERs)
- Regulatory decision-making on labeling updates, restrictions, or risk minimization measures
CIOMS and Research Ethics
In addition to pharmacovigilance, CIOMS is globally respected for its ethical guidelines in biomedical research.
CIOMS ethical guidance focuses on:
- Protection of human research participants
- Ethical conduct of clinical trials
- Safeguarding vulnerable populations
- Responsible data collection and reporting
These ethics guidelines are widely applied, especially in multinational and low-resource research settings.
.png)
Comments
Post a Comment